Citigroup Reiterates Buy Rating for Bayer (FRA:BAYN)

Bayer (FRA:BAYN)‘s stock had its “buy” rating reiterated by research analysts at Citigroup in a research note issued on Thursday, January 11th.

Several other brokerages have also commented on BAYN. Barclays set a €105.00 ($129.63) price objective on shares of Bayer and gave the company a “sell” rating in a research report on Monday, November 6th. Goldman Sachs Group set a €125.00 ($154.32) price objective on shares of Bayer and gave the company a “buy” rating in a research report on Tuesday, November 7th. UBS Group set a €125.00 ($154.32) price objective on shares of Bayer and gave the company a “buy” rating in a research report on Monday, November 6th. Berenberg Bank set a €124.00 ($153.09) price target on shares of Bayer and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Finally, Jefferies Group set a €137.00 ($169.14) price target on shares of Bayer and gave the stock a “buy” rating in a research report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the stock. Bayer currently has a consensus rating of “Buy” and an average target price of €121.71 ($150.26).

Shares of Bayer (BAYN) traded down €1.46 ($1.80) during trading on Thursday, hitting €102.00 ($125.93). 2,816,213 shares of the company traded hands. The stock has a market cap of $84,010.00 and a price-to-earnings ratio of 24.11. Bayer has a 52-week low of €101.45 ($125.25) and a 52-week high of €123.82 ($152.86).

ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/02/bayer-bayn-earns-buy-rating-from-citigroup.html.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply